#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Diffuse large B-cell lymphoma refractory Adenocarcinoma pancreas Neonatal alloimmune thrombocytopenia Skin angiosarcoma Alveolar proteinosis Chronic granulomatous disease IPEX syndrome Marginal zone lymphoma VEXAS syndrome Penile squamous cell carcinoma Familial hypertriglyceridaemia Cushing's syndrome Cluster headache Oesophageal adenocarcinoma stage III Cortical dysplasia More trials…

    Learn about Rare Diseases

    Glycogen storage disease type II – Diagnostics Mucopolysaccharidosis I – Treatment Pelizaeus-Merzbacher disease – Life with Disease Leiomyosarcoma – Treatment Burkitt’s lymphoma – Treatment Focal segmental glomerulosclerosis – Life with Disease Alport’s syndrome – Trials in Disease Amyotrophic lateral sclerosis Biotinidase deficiency – Treatment Proteus syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Somatropin Liraglutide Salmeterol Budigalimab Varnimcabtagene Autoleucel Bupivacaine Hydrochloride Human Serum Albumin 5% Deferiprone SP16 Maralixibat Chloride Enfortumab Vedotin Dactylis Glomerata Tumor Necrosis Factor-Alpha Tiotropium Glucose Clic-1901 Cart HYDROMORPHONE HYDROCHLORIDE GSKVX000000030918 Sodium Oxybate Pomalidomide More therapies…

    Learn about Your Condition

    Multiple system atrophy Leukocyte adhesion deficiency Haemorrhoids Psoriasis Weaning failure Optic atrophy Thermal burn Mucopolysaccharidosis III Mechanical ventilation Viral infection Seizure Hyperhidrosis Metastases to meninges Hyperadrenocorticism Malignant melanoma stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hepatocellular carcinoma

  • Study on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Bladder cancer
    • Gastric cancer
    Investigated Drugs:
    • Relatlimab
    • Nivolumab
    Austria Denmark Finland France Germany Italy +3

  • Study of Nivolumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Nivolumab
    Austria Belgium France Germany Italy The Netherlands +2

  • Study of Nivolumab and Ipilimumab for Patients with Advanced Liver Cancer (Hepatocellular Carcinoma) as First-Line Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Sorafenib
    • Ipilimumab
    • Lenvatinib
    Austria Belgium France Germany Italy Poland +2

  • Study on the Safety and Effectiveness of 166Holmium Radiation Therapy with Atezolizumab and Bevacizumab for Patients with Non-Resectable Liver Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Human Albumin As Macroaggregates
    • Bevacizumab
    • Atezolizumab
    France

  • Study of Durvalumab, Tremelimumab, and Lenvatinib with TACE for Patients with Liver Cancer (Hepatocellular Carcinoma)

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Tremelimumab
    • Durvalumab
    • Infliximab
    Belgium France Germany Italy Portugal Spain

  • Study of Nivolumab, Relatlimab and Bevacizumab combination for patients with untreated advanced or metastatic liver cancer (hepatocellular carcinoma)

    Not recruiting

    1 1 1
    Investigated Drugs:
    • Relatlimab
    • Bevacizumab
    • Nivolumab
    France Germany Italy Poland Spain
Previous Page
1 … 8 9 10 11 12 … 15
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!